128 related articles for article (PubMed ID: 16120621)
21. Prospective efficacy and safety study of neoadjuvant gemcitabine with capecitabine combination chemotherapy for borderline-resectable or unresectable locally advanced pancreatic adenocarcinoma.
Lee JL; Kim SC; Kim JH; Lee SS; Kim TW; Park DH; Seo DW; Lee SK; Kim MH; Kim JH; Park JH; Shin SH; Han DJ
Surgery; 2012 Nov; 152(5):851-62. PubMed ID: 22682078
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of clinical factors and treatment results in patients with advanced pancreatic cancer.
Brasiūnas V; Brasiūniene B; Juozaityte E; Barauskas G
Medicina (Kaunas); 2004; 40(11):1074-80. PubMed ID: 15547308
[TBL] [Abstract][Full Text] [Related]
23. Comparison of treatment patterns, resource utilization, and cost of care in patients with metastatic pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine or FOLFIRINOX.
Kim GP; Parisi MF; Patel MB; Pelletier CL; Belk KW
Expert Rev Clin Pharmacol; 2017 May; 10(5):559-565. PubMed ID: 28286977
[TBL] [Abstract][Full Text] [Related]
24. Treatment patterns and outcomes in pancreatic cancer: Retrospective claims analysis.
Doleh Y; Lal LS; Blauer-Petersen C; Antico G; Pishvaian M
Cancer Med; 2020 May; 9(10):3463-3476. PubMed ID: 32212262
[TBL] [Abstract][Full Text] [Related]
25. The clinical efficacy of adjuvant systemic chemotherapy with gemcitabine in node-positive pancreatic cancer.
Kurosaki I; Hatakeyama K
Hepatogastroenterology; 2004; 51(57):634-7. PubMed ID: 15143880
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of gemcitabine for locally advanced pancreatic cancer: comparison with 5-fluorouracil-based chemoradiotherapy.
Tada M; Arizumi T; Nakai Y; Sasaki T; Kogure H; Togawa O; Matsubara S; Tsujino T; Hirano K; Sasahira N; Isayama H; Kawabe T; Omata M
Chemotherapy; 2008; 54(4):302-8. PubMed ID: 18689983
[TBL] [Abstract][Full Text] [Related]
27. Adjuvant systemic chemotherapy with gemcitabine for stage IV pancreatic cancer: a preliminary report of initial experience.
Kurosaki I; Hatakeyama K
Chemotherapy; 2005 Oct; 51(6):305-10. PubMed ID: 16224180
[TBL] [Abstract][Full Text] [Related]
28. Gemcitabine and S-1 combination chemotherapy versus gemcitabine alone for locally advanced and metastatic pancreatic cancer: a meta-analysis of randomized controlled trials in Asia.
Li Y; Sun J; Jiang Z; Zhang L; Liu G
J Chemother; 2015 Aug; 27(4):227-34. PubMed ID: 25790948
[TBL] [Abstract][Full Text] [Related]
29. Cost-Effectiveness of Nab-Paclitaxel and Gemcitabine Versus Gemcitabine Monotherapy for Patients with Unresectable Metastatic Pancreatic Cancer in Japan.
Morimoto K; Moriwaki K; Kaneyasu T; Nakayama H; Shimozuma K
Value Health Reg Issues; 2022 Mar; 28():54-60. PubMed ID: 34800832
[TBL] [Abstract][Full Text] [Related]
30. Fixed-dose rate gemcitabine alone or alternating with FOLFIRI.3 (irinotecan, leucovorin and fluorouracil) in the first-line treatment of patients with metastatic pancreatic adenocarcinoma: an AGEO randomised phase II study (FIRGEM).
Trouilloud I; Dupont-Gossard AC; Malka D; Artru P; Gauthier M; Lecomte T; Aparicio T; Thirot-Bidault A; Lobry C; Asnacios A; Manet-Lacombe S; Fein F; Dubreuil O; Landi B; Zaanan A; Bonnetain F; Taïeb J
Eur J Cancer; 2014 Dec; 50(18):3116-24. PubMed ID: 25454414
[TBL] [Abstract][Full Text] [Related]
31. The clinical effectiveness and cost-effectiveness of gemcitabine for metastatic breast cancer: a systematic review and economic evaluation.
Takeda AL; Jones J; Loveman E; Tan SC; Clegg AJ
Health Technol Assess; 2007 May; 11(19):iii, ix-xi, 1-62. PubMed ID: 17462169
[TBL] [Abstract][Full Text] [Related]
32. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial.
Oettle H; Post S; Neuhaus P; Gellert K; Langrehr J; Ridwelski K; Schramm H; Fahlke J; Zuelke C; Burkart C; Gutberlet K; Kettner E; Schmalenberg H; Weigang-Koehler K; Bechstein WO; Niedergethmann M; Schmidt-Wolf I; Roll L; Doerken B; Riess H
JAMA; 2007 Jan; 297(3):267-77. PubMed ID: 17227978
[TBL] [Abstract][Full Text] [Related]
33. [Multi-center trial of gemcitabine for 49 patients with advanced pancreatic cancer].
Sumii T; Funakoshi A; Ito T; Mizumoto K; Tanaka M; Migita Y; Sakai T; Shinozaki H; Yamaguchi H; Niyahara T; Muranaka T; Eriguchi N; Ueki T;
Gan To Kagaku Ryoho; 2003 Jul; 30(7):971-6. PubMed ID: 12894712
[TBL] [Abstract][Full Text] [Related]
34. Improvement of long-term outcomes in pancreatic cancer and its associated factors within the gemcitabine era: a collaborative retrospective multicenter clinical review of 1,082 patients.
Kuroda T; Kumagi T; Yokota T; Seike H; Nishiyama M; Imai Y; Inada N; Shibata N; Imamine S; Okada S; Koizumi M; Yamanishi H; Azemoto N; Miyaike J; Tanaka Y; Tatsukawa H; Utsunomiya H; Ohno Y; Miyake T; Hirooka M; Furukawa S; Abe M; Ikeda Y; Matsuura B; Hiasa Y; Onji M;
BMC Gastroenterol; 2013 Aug; 13():134. PubMed ID: 24256464
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness analysis of treatments for metastatic pancreatic cancer based on PRODIGE and MPACT trials.
Zhou J; Zhao R; Wen F; Zhang P; Wu Y; Tang R; Chen H; Zhang J; Li Q
Tumori; 2016 Jun; 2016(3):294-300. PubMed ID: 27056335
[TBL] [Abstract][Full Text] [Related]
36. Comparison of 5-FU and leucovorin to gemcitabine in the treatment of pancreatic cancer.
Klein B; Sadikov E; Mishaeli M; Levin I; Figer A
Oncol Rep; 2000; 7(4):875-7. PubMed ID: 10854561
[TBL] [Abstract][Full Text] [Related]
37. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Conroy T; Desseigne F; Ychou M; Bouché O; Guimbaud R; Bécouarn Y; Adenis A; Raoul JL; Gourgou-Bourgade S; de la Fouchardière C; Bennouna J; Bachet JB; Khemissa-Akouz F; Péré-Vergé D; Delbaldo C; Assenat E; Chauffert B; Michel P; Montoto-Grillot C; Ducreux M; ;
N Engl J Med; 2011 May; 364(19):1817-25. PubMed ID: 21561347
[TBL] [Abstract][Full Text] [Related]
38. Survival outcomes in patients with early stage, resected pancreatic cancer - a comparison of gemcitabine- and 5-fluorouracil-based chemotherapy and chemoradiation regimens.
Kizilbash SH; Ward KC; Liang JJ; Jaiyesimi I; Lipscomb J
Int J Clin Pract; 2014 May; 68(5):578-89. PubMed ID: 24472057
[TBL] [Abstract][Full Text] [Related]
39. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
[TBL] [Abstract][Full Text] [Related]
40. Budget impact model of adding erlotinib to a regimen of gemcitabine for the treatment of locally advanced, nonresectable or metastatic pancreatic cancer.
Danese MD; Reyes C; Northridge K; Lubeck D; Lin CY; O'Connor P
Clin Ther; 2008 Apr; 30(4):775-84. PubMed ID: 18498925
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
